387 related articles for article (PubMed ID: 29618309)
1. Genetics and Gene Therapy of Anderson-Fabry Disease.
Simonetta I; Tuttolomondo A; Di Chiara T; Miceli S; Vogiatzis D; Corpora F; Pinto A
Curr Gene Ther; 2018; 18(2):96-106. PubMed ID: 29618309
[TBL] [Abstract][Full Text] [Related]
2. Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.
Marshall J; Ashe KM; Bangari D; McEachern K; Chuang WL; Pacheco J; Copeland DP; Desnick RJ; Shayman JA; Scheule RK; Cheng SH
PLoS One; 2010 Nov; 5(11):e15033. PubMed ID: 21124789
[TBL] [Abstract][Full Text] [Related]
3. Cardiac abnormalities in Anderson-Fabry disease and Fabry's cardiomyopathy.
Morrissey RP; Philip KJ; Schwarz ER
Cardiovasc J Afr; 2011; 22(1):38-44. PubMed ID: 21298206
[TBL] [Abstract][Full Text] [Related]
4. Human α-Galactosidase A Mutants: Priceless Tools to Develop Novel Therapies for Fabry Disease.
Modrego A; Amaranto M; Godino A; Mendoza R; Barra JL; Corchero JL
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204583
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Strategy for Fabry Disease by Intravenous Administration of Adeno-Associated Virus 9 in a Symptomatic Mouse Model.
Hayashi Y; Sehara Y; Watano R; Ohba K; Takayanagi Y; Sakiyama Y; Muramatsu K; Mizukami H
Hum Gene Ther; 2024 Mar; 35(5-6):192-201. PubMed ID: 38386497
[TBL] [Abstract][Full Text] [Related]
6. First two years of reimbursed enzyme replacement therapy in the treatment of Fabry disease in Poland.
Nowicki M; Komar M; Kusztal M; Mizia-Stec K; Liberek T; Małyszko J; Muras-Szwedziak K; Pawlaczyk K; Podolec P; Sławek J
F1000Res; 2021; 10():841. PubMed ID: 34745562
[TBL] [Abstract][Full Text] [Related]
7. Extracellular vesicles from recombinant cell factories improve the activity and efficacy of enzymes defective in lysosomal storage disorders.
Seras-Franzoso J; Díaz-Riascos ZV; Corchero JL; González P; García-Aranda N; Mandaña M; Riera R; Boullosa A; Mancilla S; Grayston A; Moltó-Abad M; Garcia-Fruitós E; Mendoza R; Pintos-Morell G; Albertazzi L; Rosell A; Casas J; Villaverde A; Schwartz S; Abasolo I
J Extracell Vesicles; 2021 Mar; 10(5):e12058. PubMed ID: 33738082
[TBL] [Abstract][Full Text] [Related]
8. Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice.
Ioannou YA; Zeidner KM; Gordon RE; Desnick RJ
Am J Hum Genet; 2001 Jan; 68(1):14-25. PubMed ID: 11115376
[TBL] [Abstract][Full Text] [Related]
9. Early renal failure in childhood in a male with Fabry disease.
Hogh JN; Ebrahim H; Moochhala S; Ramaswami U
BMJ Case Rep; 2022 May; 15(5):. PubMed ID: 35537774
[TBL] [Abstract][Full Text] [Related]
10. Fasudil alleviates the vascular endothelial dysfunction and several phenotypes of Fabry disease.
Choi JB; Seol DW; Do HS; Yang HY; Kim TM; Byun YG; Park JM; Choi J; Hong SP; Chung WS; Suh JM; Koh GY; Lee BH; Wee G; Han YM
Mol Ther; 2023 Apr; 31(4):1002-1016. PubMed ID: 36755495
[TBL] [Abstract][Full Text] [Related]
11. A case of female Fabry disease revealed by renal biopsy.
Aratani S; Yamakawa H; Suzuki S; Otsuka T; Sakai Y; Shimizu A; Tsuruoka S
CEN Case Rep; 2020 Feb; 9(1):24-29. PubMed ID: 31542871
[TBL] [Abstract][Full Text] [Related]
12. Replacement of alpha-galactosidase A in Fabry disease: effect on fibroblast cultures compared with biopsied tissues of treated patients.
Keslová-Veselíková J; Hůlková H; Dobrovolný R; Asfaw B; Poupetová H; Berná L; Sikora J; Golán L; Ledvinová J; Elleder M
Virchows Arch; 2008 Jun; 452(6):651-65. PubMed ID: 18351385
[TBL] [Abstract][Full Text] [Related]
13. Infertility in Fabry's Disease: role of hypoxia and inflammation in determining testicular damage.
Sansone L; Barreca F; Belli M; Aventaggiato M; Russo A; Perrone GA; Russo MA; Tafani M; Frustaci A
Front Endocrinol (Lausanne); 2024; 15():1340188. PubMed ID: 38455658
[TBL] [Abstract][Full Text] [Related]
14. Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice.
Ohshima T; Schiffmann R; Murray GJ; Kopp J; Quirk JM; Stahl S; Chan CC; Zerfas P; Tao-Cheng JH; Ward JM; Brady RO; Kulkarni AB
Proc Natl Acad Sci U S A; 1999 May; 96(11):6423-7. PubMed ID: 10339603
[TBL] [Abstract][Full Text] [Related]
15. Rapid Clathrin-Mediated Uptake of Recombinant α-Gal-A to Lysosome Activates Autophagy.
Ivanova MM; Dao J; Kasaci N; Adewale B; Fikry J; Goker-Alpan O
Biomolecules; 2020 May; 10(6):. PubMed ID: 32486191
[TBL] [Abstract][Full Text] [Related]
16. Cochleovestibular Signs As the First Manifestation of Fabry Disease: A Case Report and Literature Review.
Zakaria Y; Yahya N; Kissani N
Cureus; 2024 Mar; 16(3):e57289. PubMed ID: 38690505
[TBL] [Abstract][Full Text] [Related]
17. Sometimes when you hear hoof beats, it could be a zebra: consider the diagnosis of Fabry disease.
Burton JO; Dormer JP; Binns HE; Pickering WP
BMC Nephrol; 2012 Jul; 13():73. PubMed ID: 22849389
[TBL] [Abstract][Full Text] [Related]
18. A systematic review on safety and efficacy of Migalastat for the treatment of Fabry's disease.
Majid H; Verma N; Bhandari S; Gupta S; Nidhi A
Expert Opin Pharmacother; 2024 May; ():. PubMed ID: 38753367
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate reduces antibody responses to recombinant human alpha-galactosidase A therapy in a mouse model of Fabry disease.
Garman RD; Munroe K; Richards SM
Clin Exp Immunol; 2004 Sep; 137(3):496-502. PubMed ID: 15320898
[TBL] [Abstract][Full Text] [Related]
20. Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease.
Moore DF; Altarescu G; Herscovitch P; Schiffmann R
BMC Neurol; 2002 Jun; 2():4. PubMed ID: 12079501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
